Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa1613683
   PubMed Web of Science ®Google Scholar
• Tamura D, Jinnouchi N, Abe M, et al. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice. Int J Clin Oncol. 2020;25(5):899–905. doi:10.1007/s10147-019-01613-9
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Suzuki K, Hiraide M, et al. Association of immune-related adverse events with pembrolizumab efficacy in the treatment of advanced urothelial carcinoma. Oncology. 2020;98(4):237–242. doi:10.1159/000505340
   PubMed Web of Science ®Google Scholar
• Patterson K, Prabhu V, Xu R, et al. Cost-effectiveness of pembrolizumab for patients with advanced, unresectable, or metastatic urothelial cancer ineligible for cisplatin-based therapy. Eur Urol Oncol. 2019;2(5):565–571. doi:10.1016/j.euo.2018.09.009
   PubMed Web of Science ®Google Scholar
• Narita T, Hatakeyama S, Numakura K, et al. Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: a multicenter retrospective study. Int J Urol. 2021;28(9):899–905. doi:10.1111/iju.14601
   PubMed Web of Science ®Google Scholar
• Narayanan S, Harshman LC, Srinivas S. Second-line therapies in metastatic urothelial carcinoma. Hematol Oncol Clin North Am. 2015;29(2):341–359. doi:10.1016/j.hoc.2014.10.007
   PubMed Web of Science ®Google Scholar
• Doshi GK, Bhanegaonkar A, Kearney M, et al. Treatment sequencing patterns in patients with metastatic urothelial cancer treated in the community practice setting in the United States: SPEAR-bladder (study informing treatment pathway dEcision in bladder cAnceR). Clinicoecon Outcomes Res. 2020;12:645–656. doi:10.2147/CEOR.S264942
   PubMed Web of Science ®Google Scholar
• Vellinga A, Cormican M, Hanahoe B, Bennett K, Murphy AW. Opt-out as an acceptable method of obtaining consent in medical research: a short report. BMC Med Res Methodol. 2011;11(1):40. doi:10.1186/1471-2288-11-40
   PubMed Web of Science ®Google Scholar
• Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211–214. doi:10.1016/S1470-2045(10)70275-8
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi:10.1159/000180580
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kim HJ, Lonjon G, Zhu Y; written on behalf of AME Big-Data Clinical Trial Collaborative Group. Balance diagnostics after propensity score matching. Ann Transl Med. 2019;7(1):16. doi:10.21037/atm.2018.12.10
   PubMed Web of Science ®Google Scholar
• Miyake M, Iida K, Nishimura N, et al. Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. BMC Cancer. 2021;21(1):266. doi:10.1186/s12885-021-07966-7
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679. doi:10.1002/sim.6607
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Necchi A, de Wit R, et al. Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the Phase 3 KEYNOTE-045 trial. J Clin Oncol. 2021;39(15 suppl):4532. doi:10.1200/JCO.2021.39.15_suppl.4532
   Web of Science ®Google Scholar
• Kato M, Kobayashi T, Matsui Y, et al. Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab. Int J Urol. 2021;28(12):1261–1267. doi:10.1111/iju.14686
   PubMed Web of Science ®Google Scholar
• Amatya AK, Fiero MH, Bloomquist EW, et al. Subgroup analyses in oncology trials: regulatory considerations and case examples. Clin Cancer Res. 2021;27(21):5753–5756. doi:10.1158/1078-0432.CCR-20-4912
   PubMed Web of Science ®Google Scholar
• Furubayashi N, Negishi T, Sakamoto N, et al. Organ-specific tumor response to pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy. Onco Targets Ther. 2021;14:1981–1988. doi:10.2147/OTT.S299724
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhou Q, Xie K, et al. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer. J Exp Clin Cancer Res. 2021;40(1):203. doi:10.1186/s13046-021-01989-5
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang J, Ruan W, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J Clin Invest. 2020;130(12):6278–6289. doi:10.1172/JCI139597
   PubMed Web of Science ®Google Scholar
• Miyake M, Owari T, Hori S, Nakai Y, Fujimoto K. Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma. Res Rep Urol. 2018;10:251–261. doi:10.2147/RRU.S173027
   PubMed Web of Science ®Google Scholar
• Bonfante G, Fantinel E, Masini C, Bergamaschi F, Micali S, Rocco B. Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: a case report. Urol Case Rep. 2020;34:101444. doi:10.1016/j.eucr.2020.101444
   PubMed Web of Science ®Google Scholar
• Ishiyama Y, Takagi T, Yoshida K, et al. Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors. IJU Case Rep. 2019;3(1):25–27. doi:10.1002/iju5.12133
   PubMedGoogle Scholar
• Fukushima H, Kijima T, Fukuda S, et al. Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: a preliminary study. Cancer Med. 2020;9(22):8355–8363. doi:10.1002/cam4.3445
   PubMed Web of Science ®Google Scholar